The GLP-1-Based Therapeutics Summit is the Ultimate Industry Forum for Developers of GLP-1-Based Therapeutics Across Different Indications

The GLP-1-Based Therapeutics Summit is a once-a-year event, uniting 60+ industry experts to help advance more specialized, durable, and efficacious GLP-1s while investigating commercial opportunities to crystallize pipeline strategy and indication expansion.

Grab your copy of the full agenda

Amidst the resounding success of Novo’s SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.

If you are looking to differentiate your GLP-1 products, forge new relationships with fellow GLP-1 developers, or discover the newest innovations in improving the tolerability, efficacy, and durability of GLP-1s, there has never been a more appropriate time to unite and navigate this rapidly evolving space at the GLP-1-Based Therapeutics Summit this May!

Key Highlights:

Unraveling Exciting Opportunities to Apply GLP-1 Receptor Agonists Across a Wide Range of Indications
Including cardiovascular, renal, obstructive sleep apnea, MASH, and neurodegenerative diseases with Eli Lily, D&D Pharmatech, and Altimmune

Optimizing the Efficacy of GLP-1-Based Therapeutics
Hear the newest innovations raising the benchmark for more successful weight loss with Diasome Pharmaceuticals and BioAge Labs

Developing a Robust Commercial Strategy 
Differentiate your GLP-1 products from your competitors, to effectively target specific patient segments with Altimmune and Regor Therapeutics